In exchange, Hengrui will receive $500m in upfront fees and will be eligible for approximately $12bn in development, ...

GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

GlaxoSmithKline has announced the purchase of 306,478 of its own ordinary shares as part of its ongoing buyback programme. This transaction, executed through Merrill Lynch International, is part of a ...

GSK Egypt posted non-consolidated net profits after tax of EGP 71.33 million in H1-25, an annual drop from EGP 99.54 million. Meanwhile, the EPS declined to EGP 0.85 from EGP 1.19. In April-June 2025, ...

Arab Finance: GlaxoSmithKline Egypt (GSK–Egypt) logged consolidated net profits for controlling interest of EGP 65.060 ...

GlaxoSmithKline ( ($GB:GSK) ) just unveiled an update. GSK plc announced the acquisition of ordinary shares by several key executives under the ...

British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority ...

With the stock currently priced at Rs 2,724.90, GlaxoSmithKline Pharmaceuticals shows significant activity in today's session ...

GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

GSK’s share price is still significantly down on the year, despite very robust H1 results, leaving it looking extremely ...